The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Chuikyo Rep Interview 2-3 - With 80% Generic Share, Now Is the Time to Revisit LLP Copay, Says Payer Rep
October 13, 2023
-
REGULATORY MHLW Panel Proposes Assessing Generic Makers’ Efforts toward Stable Supplies, Reflecting Results in Pricing
October 12, 2023
-
REGULATORY Vyvgart, Dysval Braced for Price Cuts after CEA, No Change for Ondexxya
October 12, 2023
-
ACADEMIA G1 Product Info Could Disappear after Withdrawal, PMDA Website Should Retain Posting: Pharmacist
October 11, 2023
-
ORGANIZATION Chuikyo Rep Interview 2-2 - Payer Says Drug Prices Not Only Cause of Lag/Loss, Industry Proposal Needs More Details
October 11, 2023
-
ORGANIZATION Chuikyo Rep Interview 2-1 - As Japan Sees More Pricey Meds, Kenporen Director Wants Rethink of Health Coverage
October 10, 2023
-
ORGANIZATION Global CEOs Want Positive Sign from Japan, Sentiments Drive Decisions: EFPIA Chief
October 6, 2023
-
REGULATORY Post-Launch Re-Pricing Likely the Focus of Chuikyo Leqembi Discussions
October 5, 2023
-
ORGANIZATION Chuikyo Rep Interview 1 - JPA Vice President Warns against Rushed Dabate on Yakkasa, 2% Buffer Zone
October 4, 2023
-
BUSINESS Drug Makers Discontinue Sales of Alesion Dry Syrup, Generic Versions
October 3, 2023
-
REGULATORY As Copay Debate Picks Up Steam, MHLW Floats 4 Ideas for Coverage Reform
October 2, 2023
-
REGULATORY Japan Seeking Solutions as Lab Monkey Shortage, Price Surge Threaten to Stymie Drug Development
October 2, 2023
-
REGULATORY Guidelines Should Urge Drug Makers to Explain Solo-Wholesaler Decisions: Panel Members
September 29, 2023
-
REGULATORY As Chuikyo Begins Pricing Debate of Leqembi, Panelists Urge Safety, Fair Access
September 28, 2023
-
REGULATORY Japan Agrees to Buy Extra 10 Million Doses of Pfizer COVID Vaccine
September 27, 2023
-
BUSINESS Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
-
REGULATORY Leqembi Subject to Cost Control Rule for Potential Big Sellers, MHLW Still Set to Meet Listing Deadline
September 26, 2023
-
REGULATORY Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
-
ACADEMIA Academic Society Condemns Off-Label Use of GLP-1 Diabetes Drugs as Shipment Curbs Persist
September 25, 2023
-
BUSINESS LTL Pharma Sees “G1” LLP Price Cuts as Business Opportunity: President
September 22, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…